Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Cancer Conversations
Experts Discuss Evolving Treatment Paradigms and Ongoing Clinical Trials in Mantle Cell Lymphoma
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 7, 2021 Expiration: September 6, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Julie M. Vose, MD, MBA
Program Director
Christopher R. Flowers, MD, MS
John P. Leonard, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan therapeutic strategies for patients with MCL based on diagnostic classification, patient age and fitness, and risk stratification
  • Integrate the available clinical data, treatment guidelines, and expert recommendations when selecting treatment of newly diagnosed and R/R MCL
  • Recognize and manage adverse events associated with current and recently approved systemic therapies in MCL
  • Evaluate the available clinical data on promising investigational agents and treatment approaches for appropriate patients with MCL including clinal trial enrollment

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Genentech, Janssen/PCYC, Johnson & Johnson, Kite, Morphosys, and Roche and funds for research support from AstraZeneca and Kite.

Faculty

Christopher R. Flowers, MD, MS

Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS, has disclosed that he has received consulting fees from AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Genmab, Gilead Sciences, Karyopharm, Pharmacyclics/Janssen, SeaGen, and Spectrum and funds for research support from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Genentech/Roche, Gilead Sciences, Guardant, Iovance, Janssen, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, and Ziopharm.
John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

John P. Leonard, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Epizyme, Genentech/Roche, GenMab, Gilead Sciences/Kite, Incyte, Janssen, Karyopharm, MEI Pharma, Miltenyi, Regeneron, and Sutro and funds for research support from Genentech.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Target Audience

This educational program is intended for hematologists, oncologists, and advanced practitioners in hematology/oncology who care for patients with MCL.

Goal

The goal of this activity is to educate hematologists, oncologists, and advanced practitioners in hematology/oncology about the recent developments in the care of MCL and incorporating new data and new therapies into their patient treatment plans.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 07, 2021, through September 06, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Cancer Conversations
Experts Discuss Evolving Treatment Paradigms and Ongoing Clinical Trials in Mantle Cell Lymphoma
  • CME

Loading...
Watch this on-demand webcast of a live CCO webinar to hear a panel of experts discuss the current treatment landscape and ongoing clinical trials in mantle cell lymphoma.
Julie M. Vose, MD, MBA
Program Director
Christopher R. Flowers, MD, MS
John P. Leonard, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 7, 2021 Expiration: September 6, 2022

Related Content

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the initial management of light-chain amyloidosis

Vaishali Sanchorawala, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of light-chain amyloidosis at relapse

Ankit Kansagra, MD Released: January 18, 2022

Ashley Leak Bryant, PhD, RN, OCN, FAAN, shares strategies for managing lower-risk myelodysplastic syndromes in this commentary from Clinical Care Options (CCO)

Ashley Leak Bryant, PhD, RN, OCN, FAAN Released: January 14, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings